Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 09/28/15 | 8-K | Current report filing |
|
14 | |
| 09/25/15 | 8-K | Current report filing |
|
4 | |
| 09/21/15 | 8-K | Current report filing |
|
7 | |
| 09/16/15 | 8-K | Current report filing |
|
9 | |
| 09/10/15 | 8-K | Current report filing |
|
7 | |
| 09/08/15 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
64 | |
| 09/03/15 | 8-K | Current report filing |
|
68 | |
| 09/03/15 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses |
|
31 | |
| 09/02/15 | 8-K | Current report filing |
|
11 | |
| 08/26/15 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses |
|
16 |
